Welwyn Garden City, UK, 21st April 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with a third (undisclosed) pharmaceutical company. The research, which will take advantage of CN Bio’s full viral lifecycle model of Hepatitis B, Quantum-B®, will be performed by CN Bio in the company’s newly opened Containment Level 3 laboratory in Welwyn Garden City, UK.
- CN Bio expands service offering to support oncology drug discovery 5th October 2021
- Changing Times, Why Pharmacokinetics Matter in Drug Discovery 15th September 2021
- CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University 27th July 2021